Evidence map›Paper›PMID 27909343›Full record

Trial reportLeukemia2017

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.

J Edelmann, E Tausch, D A Landau, S Robrecht, J Bahlo, K Fischer, A M Fink, J Bloehdorn, K Holzmann, S Böttcher and 8 more

Abstract readClinical TrialLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. NAT10-Mediated ac4C Modification of circANKRD12 Reprograms the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Review
  4. Impact of Low-BurdenFrontiers in oncology · 2022
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

J EdelmannInternal Medicine III, Ulm University, Ulm, Germany.
E TauschInternal Medicine III, Ulm University, Ulm, Germany.
D A LandauDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
S RobrechtInternal Medicine I, University of Cologne, Cologne, Germany.
J BahloInternal Medicine I, University of Cologne, Cologne, Germany.
K FischerInternal Medicine I, University of Cologne, Cologne, Germany.
A M FinkInternal Medicine I, University of Cologne, Cologne, Germany.
J BloehdornInternal Medicine III, Ulm University, Ulm, Germany.
K HolzmannCenter for Clinical Research, Genomics Core Facility, Ulm University, Ulm, Germany.
S BöttcherSecond Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
L WernerBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA.
M KnebaSecond Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
J G GribbenBarts Cancer Institute, Queen Mary University of London, London, UK.
D S NeubergBiostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA.
C J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
M HallekInternal Medicine I, University of Cologne, Cologne, Germany.
H DöhnerInternal Medicine III, Ulm University, Ulm, Germany.
S StilgenbauerInternal Medicine III, Ulm University, Ulm, Germany.

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI REED, JOHN C · 2000 to 2016
$59.5M
Personal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6M
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4M
(PQD1) lmpact of cytotoxic and targeted therapy on clonal evolution of CLLR01CA184922 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2014 to 2017
$2.2M
The role of the SF3B1 splicing factor in chronic lymphocytic leukemiaR01HL116452 · NHLBI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2013 to 2017
$2.1M
Defining the impact of clonal evolution on chronic lymphocytic leukemiaR01CA182461 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2014 to 2018
$1.8M
The role of epigenetic heterogeneity in CLL evolution Admin supplementK01ES025431 · NIEHS · WEILL MEDICAL COLL OF CORNELL UNIV · PI LANDAU, DAN · 2014 to 2018
$982k
NCI NIH HHS P01 CA081534NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA182461NCI NIH HHS R01 CA184922NCI NIH HHS U10 CA180861NHLBI NIH HHS R01 HL116452NIEHS NIH HHS K01 ES025431
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA Copy Number VariationsClone CellsHumansLeukemia, Lymphocytic, Chronic, B-CellMutationRituximabTreatment OutcomeTumor Suppressor Protein p53RituximabTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID27909343
PMCPMC5332302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.